Novo Nordisk, the maker of Ozempic and Wegovy weight-loss drugs, just regained the title as Europe’s most valuable company ...

Novo Nordisk and Deep Apple Therapeutics Inc. have entered a research collaboration and exclusive license agreement.

Septerna, Inc. (NASDAQ:SEPN), operating within the biotechnology space, continues to attract attention amid notable activity ...

Learn about May 2025’s top biotech deals, featuring major collaborations in RNA interference technology, small molecules, and antibodies.

The article " Analysts Think These Stocks Could More Than Double in Value " first appeared on MarketBeat.

Shares of Septerna, Inc. (SEPN) have gained 57.8% over the past four weeks to close the last trading session at $9.42, but there could still be a solid upside left in the stock if short-term price ...

Septerna's partnership with Novo Nordisk is a strong endorsement, but the $195m upfront is modest (by Big Pharma standards) and milestone payments are not guaranteed. The company’s innovative ...

Septerna's partnership with Novo Nordisk validates its GPCR drug discovery platform and injects $195 million in upfront cash, with potential for more than $2 billion in milestone payments.

The analysis of recent analyst actions sheds light on the perception of Septerna by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ...

Photo by Towfiqu barbhuiya/Pexels The deal could be worth up to $2.2 billion for Septerna. This includes more than $200 million in upfront and short-term milestone payments, plus future rewards tied ...

Novo Nordisk and Septerna have announced a new partnership worth $2.2bn to develop oral small molecule drugs for type 2 diabetes, obesity and other cardiometabolic diseases. The exclusive global ...

May 15, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today highlighted key business updates ...